Scientists Create Antibody That Defeats Coronavirus in Lab
- Sick but want to avoid the Doctor's Office? Get FREE medical help from home!
- 12 PROVINCES/ CITIES TO CONTINUE WITH SOCIAL DISTANCING FOR AT LEAST 1 WEEK
- More than 1,000 US coronavirus deaths, Prince Charles tests positive for COVID-19
- Coronavirus: Are diabetics more prone to Covid-19?
- Coronavirus updates, March 25: Vietnam’s confirmed positive cases rise to 134
- Warning: People must not buy chloroquine to self-medicate for coronavirus
- COVID-19 updates: Italy overtakes China's death, Vietnam confirms 9 new cases
- Vietnam reports all 16 COVID-19 patients as recovered
- Vietnam offers free treatment to COVID-19 patients
- Vietnam’s scientists successfully develops quick coronavirus test kit
- Coronavirus disease (COVID-19) advice: When and how to use masks
- Vietnam: Health Ministry’s guidance for COVID-19 prevention, control
- How to protect yourself from COVID-19 virus?
- COVID-19 News: Italy, France report biggest spike of COVID-19 cases since outbreak
- Coronavirus gets official name from WHO: COVID-19
- Japan reports 10 more coronavirus cases aboard quarantined cruise ship
- Coronavirus news and live updates: 24580 confirmed cases, 493 deaths
- Vietnam confirms 10th patient infected with novel coronavirus
0 Bình luận
The discovery of an antibody that has the ability to defeat coronavirus, the virus that causes COVID-19, has been hailed as "groundbreaking".
Scientists from Dutch institutions Utrecht University, Erasmus Medical Center and Harbour BioMed made the discovery, which was made public in a study published in scientific journal Nature Communications on Monday.
The study found that the 'neutralising monoclonal antibody' known as 47D11 has been found to prevent SARS-CoV-2 from entering cultured cells.
While that’s early in the drug development process -- before animal research and human trials -- the antibody may help prevent or treat Covid-19 and related diseases in the future, either alone or in a drug combination, according to a study published Monday in the journal Nature Communications.
Most therapeutic antibodies are developed first in other species, and require extensive additional work to 'humanise' them, Utrecht University explains - but 47D11 bucks that trend.
Dr Frank Grosveld, chief scientific officer at Harbour BioMed and the study's co-lead author, says 47D11's 'fully human' make-up has a range of benefits in the creation of a COVID-19 treatment.
"The antibody used in this work is 'fully human', allowing development to proceed more rapidly and reducing the potential for immune-related side effects," he said.
"Such a neutralising antibody has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus.
"This discovery provides a strong foundation for additional research to characterise this antibody and begin development as a potential COVID-19 treatment."
In lab tests, 47D11 was also found to be effective at blocking infection from SARS-CoV, the virus that causes SARS - a sign it could be used to treat a range of viral illnesses.
"This cross-neutralising feature of the antibody is very interesting, and suggests it may have potential in mitigation of diseases caused by future-emerging related coronaviruses," co-lead author Dr Berend-Jan Bosch says.
Dr Jingsong Wang, CEO of Harbour BioMed, labelled the discovery of 47D11 "groundbreaking".
He says the team is now "pursuing several other research avenues" in an effort to address the "urgent public health need" brought on by the COVID-19 outbreak.
Coronavirus is a global pandemic that has infected 3.6 million people and resulted in the deaths of more than 251,000.
As of last week, there were seven candidate vaccines in clinical evaluation and 82 in pre-clinical evaluation around the world, according to the World Health Organization.
It's estimated that it will take 12 to 18 months for a vaccine to be rolled out worldwide.
Source: Bloomberg, Hub